A Phase 3 interventional study of Brexanolone in Post Partum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 17 sites in United States. Open to female participants aged 15 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 159th largest by enrollment of the 198 interventional ones that give a count, is one of 14 that started in 2018, is one of 12 in phase 3, and was the 99th registered.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 15 Years to 17 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 14 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 8 studies filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a 60-hour single continuous IV infusion of brexanolone, at 30 mcg/kg/hour (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
Drug: Brexanolone
Administered as IV infusion.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.
Time frame: From first dose of study drug up to end of follow-up period (up to Day 30)
Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
AUC From Time Zero to Infinity (AUCinf)
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Maximum (Peak) Plasma Concentration (Cmax)
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Time at Maximum (Peak) Plasma Concentration (Tmax)
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)
Given that brexanolone is infused to steady-state plasma concentrations, the model-predicted steady-state drug concentration in the plasma during constant-rate infusion value also represents the predicted maximum plasma concentration at the highest infused dose (90 ug/kg/h).
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)
Cavg was evaluated as the time-weighted average plasma concentrations of brexanolone over the interval.
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Half-Life of First Elimination Phase of Brexanolone (Thalf)
Half-life is the time required for half of the drug to be eliminated from the serum.
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Clearance of Brexanolone (CL/F)
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Steady-State of Volume of Distribution (Vss)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Participants took part in the study at 8 investigating sites in the United States, from 07 September 2018 to 08 January 2021.
| Milestone | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|---|
| Started | 8 | 8 | 12 |
| Completed | 8 | 8 | 11 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.
| Participants | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 4 | 3 | 5 |
| hours*nanograms per milliliter(hr*ng/mL) | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60) | 3694.9 ± 397.90 | 3516.0 ± 562.85 |
| hr*ng/mL | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| AUC From Time Zero to Infinity (AUCinf) | 4125.9 ± 481.84 | 3982.2 ± 709.70 |
| nanograms per milliliter (ng/mL) | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Maximum (Peak) Plasma Concentration (Cmax) | 85.31 ± 9.571 | 81.66 ± 13.528 |
| hour (hr) | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Time at Maximum (Peak) Plasma Concentration (Tmax) | 52.20 (52.0 to 52.4) | 52.30 (52.1 to 54.9) |
Given that brexanolone is infused to steady-state plasma concentrations, the model-predicted steady-state drug concentration in the plasma during constant-rate infusion value also represents the predicted maximum plasma concentration at the highest infused dose (90 ug/kg/h).
| ng/mL | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css) | 79.4 | 79.4 |
Cavg was evaluated as the time-weighted average plasma concentrations of brexanolone over the interval.
| ng/mL | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg) | 61.59 ± 6.639 | 58.60 ± 9.386 |
Half-life is the time required for half of the drug to be eliminated from the serum.
| hour | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Half-Life of First Elimination Phase of Brexanolone (Thalf) | 12.24 ± 0.466 | 12.55 ± 1.096 |
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
| liters per hour (L/hr) | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Clearance of Brexanolone (CL/F) | 66.86 ± 13.858 | 77.88 ± 18.026 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liters (L) | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|
| Steady-State of Volume of Distribution (Vss) | 448.1 ± 70.34 | 588.5 ± 187.53 |
Collected over From first dose of study drug up to end of follow-up period (up to Day 30). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Phase: Placebo | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Double-Blind Phase: Brexanolone | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Open-Label Phase: Brexanolone | 0/12 (0%) | 1/12 (8.3%) | 4/12 (33.3%) |
| Event | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|---|
| DizzinessNervous system disorders | 0/8 | 0/8 | 1/12 |
| Loss of consciousnessNervous system disorders | 0/8 | 0/8 | 1/12 |
| Event | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone |
|---|---|---|---|
| Infusion site painGeneral disorders | 0/8 | 2/8 | 1/12 |
| DizzinessNervous system disorders | 0/8 | 0/8 | 2/12 |
| SedationNervous system disorders | 0/8 | 1/8 | 1/12 |
| Infusion site extravasationGeneral disorders | 1/8 | 0/8 | 0/12 |
| Infusion site inflammationGeneral disorders | 1/8 | 0/8 | 0/12 |
| Infusion site swellingGeneral disorders | 1/8 | 0/8 | 0/12 |
| NauseaGastrointestinal disorders | 1/8 | 1/8 | 1/12 |
| Localized infectionInfections and infestations | 1/8 | 0/8 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/8 | 0/12 |
| Weight decreasedInvestigations | 1/8 | 0/8 | 0/12 |
The safety set included all participants administered study drug.
| Age, Continuous(years) | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone | Total |
|---|---|---|---|---|
| Mean | 16.6 ± 0.52 | 16.4 ± 0.52 | 16.3 ± 0.78 | 16.4 ± 0.63 |
| Sex: Female, Male(Participants) | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 12 | 28 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 2 |
| Not Hispanic or Latino | 8 | 6 | 12 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Double-Blind Phase: Placebo | Double-Blind Phase: Brexanolone | Open-Label Phase: Brexanolone | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 10 | 22 |
| White | 2 | 2 | 1 | 5 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Jan 2021, 28 months.
Results were first posted in Aug 2022, 1 year 7 months after primary completion. A results delay was requested in Jan 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →